XWPharma: timing therapy to biological rhythm

Wuhan-based XWPharma is developing novel formulations of existing neurology drugs designed to synchronize with the body’s natural rhythms, enabling it to avoid side effects associated with marketed agents.

Last week, XWPharma, formerly XW Laboratories Inc., raised $40 million in a series C round led by Panacea Venture, and followed the fund-raise with the Thursday appointment of Leonard Blum as president and CEO. Blum succeeds founder Jia-Ning Xiang, who will assume the role of CSO. ...